The Asian American Medical Group (AAMG), formerly known as Asian Centre for Liver Diseases & Transplantation (ACLDT), was established in 1994.
Listed on the Australian Securities Exchange since September 2009, AAMG was first established as a liver centre before its name change, following the Group’s strategic collaboration in 2012 with US-based global health enterprise UPMC. UPMC is affiliated with the University of Pittsburgh and is a pioneer in the field of transplantation.
AAMG is led Dr Tan Kai Chah, the Executive Chairman of the Group. His clinical operations are supported by a multi-disciplinary team of specialists and experienced healthcare personnel of the Group’s subsidiaries Asian American Liver Centre Pte Ltd (“AALC”) and the Asian American Radiation Oncology Pte Ltd (“AARO”).
AAMG obtained a listing on the Australian Securities Exchange on 29 September 2009 and now trades under the ticker code AJJ.
AAMG, headquartered at Gleneagles Hospital in Singapore, has three main operating segments which are the liver, radiation oncology and healthcare project management and consultancy segments.
AALC, which operates the liver segment which operates under its wholly-owned subsidiary, offers a one-stop seamless and comprehensive treatment for patients with liver and hepatobiliary diseases. With a team of highly trained specialists, state-of-the-art facilities and equipment, we provide optimal care and treatment for adults and children.
AARO, established in March 2015, offers radiation oncology clinical, consultancy and management services and is spearheaded by Dr Daniel Tan Yat Harn. Based in Singapore, AARO will drive expansion into the growing radiotherapy and oncology segment in the overseas market, at a time where there is a shortage of modern radiotherapy treatment centres.
For the clinical segments, AAMG undertakes highly complex specialist medical procedures, but also manages the full patient experience from marketing / patient education, medical concierge, billing, and hospital interaction. AAMG treats over 8,000 patients a year, 90% of whom are international patients from South-east Asia, South Asia, Indochina, the Middle East and North Asia.
AAMG also provides healthcare consultancy and management services. One notable project that AAMG is currently working on is the Zhuhai-Singapore Life Science Park, which is the development of a modern international health screening centre, multi-disciplinary medical suites, and a one-stop suite of medical aesthetic services located in the Zhuhai Free Trade Zone, Guangdong Province, China.
AAMG’s growth strategies include:
1) Organic growth of its Singapore operations – through the recruitment of more specialists. Currently, there is a growing demand for services liver diseases and cancer from the South-east Asia, Indochina and the Middle East regions.
2) Non-Organic growth through the development of overseas centres and strategic alliances in the region.
3) Diversification of services through the addition of other medical specialties and service offerings. AAMG has started offering radiation oncology clinical and consultancy services in early 2015 and has continued to strengthen its healthcare management and consultancy arm which aims to take advantage of the fast-growing healthcare market in the region.
Update financial statistics can be found by Here